Fludarabine and Cytarabine as Continuous Infusion Plus Idarubicin With Granulocyte-Colony Stimulating Factor (G-CSF) Priming for Patients Younger Than 60 Years With Resistant Acute Myeloid Leukemia
This clinical trial, sponsored by the Cooperative Study Group A for Hematology, aims to evaluate the feasibility and efficacy of a combination therapy (FLAG+Ida) in patients younger than 60 years with resistant AML. Given the high unmet medical need in this patient population, successful outcomes could position this treatment as a competitive option in the AML market, which is characterized by a growing demand for effective therapies. The trial's focus on younger patients with resistant disease may also attract interest from pharmaceutical companies looking to expand their oncology portfolios. However, the overall status of the trial remains 'unknown,' which may raise concerns regarding recruitment and potential delays in data availability.
Indication: Acute Myeloid Leukemia
Modality: small molecule
Target: Fludarabine and cytarabine as continuous infusion plus idarubicin with G-CSF priming for the treatment of resistant acute myeloid leukemia (AML).
Sponsor: Cooperative Study Group A for Hematology
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 21, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Fludarabine and cytarabine as continuous infusion plus idarubicin with G-CSF priming for the treatment of resistant acute myeloid leukemia (AML).
View original source fields
Condition raw: Acute Myeloid Leukemia
Condition normalized: Acute Myeloid Leukemia
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Fludarabine and cytarabine as continuous infusion plus idarubicin with G-CSF priming for the treatment of resistant acute myeloid leukemia (AML).
Target normalized: Fludarabine and cytarabine as continuous infusion plus idarubicin with G-CSF priming for the treatment of resistant acute myeloid leukemia (AML).